Predictive Value of Gene Expression and EGFR Mutation for Clinical Efficacy of EGFR Tyrosine Kinase Inhibitor in NSCLC

Soji Kakiuchi(Tokushima Prefectural Central Hospital), Saburo Sone(Io Therapeutics (United States)), Yasuhiko Nishioka(Tokushima University), Kazuya Kondo(Tokushima University), Akihiro Tomida(Yao Tokushukai General Hospital), Yusuke Nakamura(Mazda Motor Corporation (Japan)), Takashi Tsuruo(Chemotherapy Foundation), Masaki Hanibuchi(Tokushima University), Seiji Yano(Kanazawa University Hospital)
日本癌学会学術総会記事
January 1, 2008
Cited by 0

Related Papers

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Molecular Identification of Aggrus/T1α as a Platelet Aggregation-inducing Factor Expressed in Colorectal Tumors
|Journal of Biological Chemistry|2003|266